A small phase 2a trial of GH001, an investigational psychedelic compound, found a rapid reduction in postpartum depression symptoms. Larger studies are needed to assess safety and durability.
Parents of infants in the NICU face high rates of depression, anxiety, stress, and trauma. Are we doing enough to identify their needs—and provide meaningful mental health support?
Postpartum psychosis is a medical emergency, but temporary and treatable. In this podcast episode, survivors share early warning signs, treatment, and recovery—helping families and clinicians recognize and respond quickly.
Partners’ mental health is often overlooked in the perinatal period. Dr. Sheehan Fisher discusses why supporting all parents improves outcomes for families.
Our podcast provides an evidence-based discussion of perinatal mood and anxiety disorders during pregnancy and how to improve care for mothers and families.
Cesarean delivery is linked to a small increase in postpartum psychiatric risk, but stronger predictors—like prior mental illness—remain more clinically important.
Emerging evidence suggests perioperative esketamine may reduce postpartum depression risk and improve recovery; however, information regarding long-term efficacy and optimal use is limited.
Lavender, used historically for anxiety, stress, depression, and sleep, may provide benefits through aromatherapy or oral forms. Evidence supports potential effects, though safety and efficacy in pregnancy and breastfeeding remain unclear.
Dr. Lee S. Cohen, Director of the Ammon-Pinizzotto Center for Women's Mental Health at Massachusetts General Hospital, recently shared his insights on optimizing the likelihood of treatment for postpartum depression with Ob.Gyn News on August 27, 2024.
There is a wide range of barriers across multiple levels--individual, healthcare professional, interpersonal, organizational, political, and societal.
